Department of Pathology, The First People's Hospital of Yunnan Province, No. 157 Jinbi Road, Xishan District, Kunming, Yunnan, 650032, China.
The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650032, China.
BMC Cancer. 2024 Aug 21;24(1):1033. doi: 10.1186/s12885-024-12800-x.
Transfer RNA-derived fragments (tRFs) are short non-coding RNA (ncRNA) sequences, ranging from 14 to 30 nucleotides, produced through the precise cleavage of precursor and mature tRNAs. While tRFs have been implicated in various diseases, including cancer, their role in lung adenocarcinoma (LUAD) remains underexplored. This study aims to investigate the impact of tRF-Val-CAC-010, a specific tRF molecule, on the phenotype of LUAD cells and its role in tumorigenesis and progression in vivo.
The expression level of tRF-Val-CAC-010 was quantified using quantitative real-time polymerase chain reaction (qRT-PCR). Specific inhibitors and mimics of tRF-Val-CAC-010 were synthesized for transient transfection. Cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8), while cell invasion and migration were evaluated through Transwell invasion and scratch assays. Flow cytometry was utilized to analyze cell cycle and apoptosis. The in vivo effects of tRF-Val-CAC-010 on tumor growth and metastasis were determined through tumor formation and metastasis imaging experiments in nude mice.
The expression level of tRF-Val-CAC-010 was upregulated in A549 and PC9 LUAD cells (P < 0.01). Suppression of tRF-Val-CAC-010 expression resulted in decreased proliferation of A549 and PC9 cells (P < 0.001), reduced invasion and migration of A549 (P < 0.05, P < 0.001) and PC9 cells (P < 0.05, P < 0.01), enhanced apoptosis in both A549 (P < 0.05) and PC9 cells (P < 0.05), and increased G2 phase cell cycle arrest in A549 cells (P < 0.05). In vivo, the tumor formation volume in the tRF-inhibitor group was significantly smaller than that in the model and tRF-NC groups (P < 0.05). The metastatic tumor flux value in the tRF-inhibitor group was also significantly lower than that in the model and tRF-NC groups (P < 0.05).
This study demonstrates that tRF-Val-CAC-010 promotes proliferation, migration, and invasion of LUAD cells and induces apoptosis in vitro, however, its specific effects on the cell cycle require further elucidation. Additionally, tRF-Val-CAC-010 enhances tumor formation and metastasis in vivo. Therefore, tRF-Val-CAC-010 may serve as a novel diagnostic biomarker and potential therapeutic target for LUAD.
转移 RNA 衍生片段(tRFs)是一类短的非编码 RNA(ncRNA)序列,长度为 14 到 30 个核苷酸,通过前体和成熟 tRNA 的精确切割产生。虽然 tRFs 与多种疾病有关,包括癌症,但它们在肺腺癌(LUAD)中的作用仍未得到充分探索。本研究旨在探讨特定 tRF 分子 tRF-Val-CAC-010 对 LUAD 细胞表型的影响及其在体内肿瘤发生和进展中的作用。
使用实时定量聚合酶链反应(qRT-PCR)定量检测 tRF-Val-CAC-010 的表达水平。合成 tRF-Val-CAC-010 的特异性抑制剂和模拟物进行瞬时转染。使用细胞计数试剂盒-8(CCK-8)评估细胞增殖,通过 Transwell 侵袭和划痕实验评估细胞侵袭和迁移。流式细胞术用于分析细胞周期和细胞凋亡。通过裸鼠肿瘤形成和转移成像实验确定 tRF-Val-CAC-010 对肿瘤生长和转移的体内影响。
在 A549 和 PC9 LUAD 细胞中,tRF-Val-CAC-010 的表达水平上调(P<0.01)。抑制 tRF-Val-CAC-010 的表达导致 A549 和 PC9 细胞的增殖减少(P<0.001),A549 细胞(P<0.05,P<0.001)和 PC9 细胞(P<0.05,P<0.01)的侵袭和迁移减少,A549 细胞(P<0.05)和 PC9 细胞(P<0.05)的凋亡增加,A549 细胞的 G2 期细胞周期阻滞增加(P<0.05)。体内,tRF 抑制剂组的肿瘤形成体积明显小于模型组和 tRF-NC 组(P<0.05)。tRF 抑制剂组的转移瘤通量值也明显低于模型组和 tRF-NC 组(P<0.05)。
本研究表明,tRF-Val-CAC-010 促进 LUAD 细胞的增殖、迁移和侵袭,并诱导体外细胞凋亡,但它对细胞周期的具体影响需要进一步阐明。此外,tRF-Val-CAC-010 增强体内肿瘤的形成和转移。因此,tRF-Val-CAC-010 可能成为 LUAD 的一种新的诊断生物标志物和潜在治疗靶点。